Reduced Sampling / Reduced Testing

cGMP compliant Sampling and Testing of Starting and Packaging Materials – how to Meet EU and FDA Requirements and safe Costs in QA/QC

20-21 October 2014, Prague, Czech Republic

SPEAKERS:
Emerich Grassinger
Haupt Pharma Wülfing GmbH, Germany

Dr Matthias Heuermann
NRW Centre for Health (LZG.NRW), Germany

Dr Gerald Kindermann
F. Hoffmann-La Roche, Switzerland

Dr Michael Möhlen
Valneva Austria GmbH, Austria

Dr Bernd Renger
Bernd Renger Consulting, Germany

Dr Martin Wesch
Wesch & Buchenroth, Law Office, Germany

LEARNING GOALS:
- Regulatory Requirements for Sampling
- Design and Qualification of Sampling Areas
- Supplier Qualification as an Important Prerequisite for Reduced Sampling / Reduced Testing:
  - Supplier Audits
  - Quality Agreements
  - Specifications / Monographs / Supplier CoA
- How to Define and Optimise Sampling and Testing Procedures for
  - APIs
  - Excipients
  - Primary Packaging Materials
  - Secondary Packaging Materials
- Options for Reduced Sampling
- Options for Reduced Testing
- How to Deal with Multicompendial Testing?
Objectives

The aim of this course is to demonstrate the process of the qualification of starting materials (APIs and excipients) and packaging materials (primary and secondary) and to define the prerequisites for implementing a system for reduced sampling and reduced testing for these products. This system has to be in compliance with the actual GMP requirements in Europe and in the US, though. Case Studies will show how to define and optimise sampling and testing procedures and you will discuss further details in a parallel session with 3 workshops.

Background

Testing active pharmaceutical ingredients, excipients and packaging materials is one of the main tasks of the quality control units in the pharmaceutical industry. It must be ensured that the necessary tests are conducted on the incoming goods and that the materials are released only after their quality was judged as satisfactory.

According to the revised draft chapter 5 – Production – of the EU GMP Guide from January 2013, the selection, qualification, approval and maintenance of suppliers has to be documented and the level of control has to be proportionate to the potential risks posed by the individual materials. Manufacturers of medicinal products are responsible for testing the starting and packaging materials as described in the marketing authorisation dossier. However, it is explicitly accepted to utilise partial or full test analysis results for a material from an approved manufacturer, if the following requirements are fulfilled:

a) A formal agreement including the transport conditions to ensure the maintenance of the quality characteristics of the starting materials

b) Regularly performed audits at the production sites

c) A certificate of analysis signed by a designated person with appropriate qualifications and experience

d) Significant experience in dealing with the starting material manufacturer ("history of compliance")

e) Full analyses that are performed regularly by the medicinal product manufacturer to compare the results with the supplier’s certificate of analysis.

It is the aim of this GMP Education Course to show how these requirements can be put into practice.

Other focus areas of this course are the regulatory requirements for sampling, the design and qualification of sampling areas and the handling of varying specifications in the different pharmacopoeias for identical APIs and excipients used for finished drug products dedicated for the markets in Europe, in the US, and in Japan.

Target Audience

This GMP Education Course is directed at all those employees from quality control units in the pharmaceutical industry (including heads of quality control and laboratory managers) who are competent or responsible for sampling, testing and release of starting materials (APIs and excipients) and packaging materials (primary and secondary). This course is also of interest to personnel from quality assurance and to those employees from API, excipient or packaging material suppliers who want to inform themselves about the requirements of the pharmaceutical industry on the testing of these materials.

Programme

Regulatory Requirements for Sampling Procedures
- API and finished goods sampling
- Regulatory requirements
  - EU GMP Part 1, Chapters 4, 5, 6
  - EU GMP Part 2, Chapter 7
  - EU GMP Annex 8
  - EU GMP Annex 19
- Other regulations
  - US / FDA Requirements
  - WHO - PIC/S - ISO (former Military Standard)
- Supplier qualification and audits
  - Reduced testing

Design and Qualification of Sampling Areas for Incoming Goods Products
- Sampling area for raw materials, APIs and excipients
- Layout and design of premises and equipment
- “Cleanroom”-like classification?
- What are the appropriate environmental requirements for sampling areas?
- How to qualify and maintain sampling areas?
- Is a change of pallets/removal of cart boxes required?
- Are expectations increasing? - Lessons learned during inspections

Supplier Qualification: an important Prerequisite for Reduced Sampling and Reduced Testing
- Prerequisites
- Qualification of packaging materials
- Qualification of APIs and excipients
- Supplier qualification / Supplier audits
- Quality Agreements
- Specifications / Pharmacopoeial monographs / Supplier CoA
- Complaint Handling

Must different tests be conducted according to EP, USP, and JP, respectively?

The course programme will be completed by a lawyer’s presentation about the legal and contractual liability of suppliers for defect products

Sampling and Documentation to make the Supplier liable for Defect Products

- Legal and Contractual Liability
- Definition of a Product Defect
- Express Warranty
- Admissible Evidence
- Insurability

Case Study I: How to Define Inspection Procedures for Packaging Materials (Primary and Secondary) in the Incoming Goods Control

- Sampling Plans for printed packaging materials, glass containers, plastic containers, etc.
- AQL (Acceptable Quality Level)
- Tests required according to Ph.Eur. / USP
- Options for reduced sampling
- Options for reduced testing
- Skip lot testing

Case Study II: How to Define and Optimise Sampling and Testing Procedures for APIs and Excipients in the Incoming Goods Control

- Sampling Plans for APIs / excipients
- Verification of pharmacopeial procedures
- Options for reduced sampling
- Options for reduced testing
- Use of / NIR / Raman for an efficient control

How to Deal with Divergent Compendial Method Requirements

- ICH Q8 and the Pharmacopoeial Discussion Group
- Divergent and conflicting pharmacopoeial requirements
- CDER's MAPP 5310.7 “Acceptability of Standards from Alternative Compendia”
- How to proceed in case of missing harmonization?
- How to proof equivalence?

Parallel Sessions: Working on specific Tasks

1. Strategies/Prerequisites for Reduced Testing / Reduced Sampling
   The aim of this workshop is to evaluate in small discussion groups how the opportunities and requirements of EU GMP Annex 8 and 21 CFR Part 211 should be implemented in QA / QC.
   Moderator: Dr Bernd Renger

2. Reduced Testing / Reduced Sampling for APIs / Excipients
   Participants will discuss in small groups scenarios of different materials / suppliers / qualification status / etc. and their impact on the sampling and testing plans with regard to reduced sampling and reduced testing for APIs and excipients.
   Moderator: Emerich Grassinger

3. Reduced Testing / Reduced Sampling for Primary and Secondary Packaging Materials
   Participants will discuss in small groups scenarios of different materials / suppliers / qualification status / etc. and their impact on the sampling and testing plans with regard to reduced sampling and reduced testing for packaging.
   Moderator: Dr Gerald Kindermann

You will be able to attend 2 of these parallel sessions. Please choose the ones you would like to attend when you register for this Course.

Speakers

Emerich Grassinger
Haupt Pharma Wülfing GmbH, Germany
Emerich Grassinger works since 1995 in various positions for the pharmaceutical industry. 2002-2010 he headed several labs within Boehringer Ingelheim and was there also responsible for the Raw Material laboratory in which the testing and release of the APIs and Excipients was carried out. He led several improvement projects throughout the supply chain involving the raw material releasing process. 2010 he joined Haupt Pharma Wuelfing, where he is responsible for Quality Control, including the raw material laboratory and the sampling of incoming goods.

Dr Matthias Heuermann
NRW Centre for Health (LZG.NRW), Münster, Germany
Since 2004 Dr. Heuermann is employed as head of the Official Medicines Control Laboratory (OMCL), today within the NRW Centre for Health of the federal state North Rhine-Westphalia. He studied pharmacy and gained his PhD thesis at the University of Münster, Germany. Since 1995 Dr Heuermann is involved in national and international GMP inspections with a focus on QC laboratories and QA systems.

Dr Gerald Kindermann
F. Hoffmann-La Roche, Basel, Switzerland
Dr Gerald Kindermann is Product Quality Manager at the Global Quality Group at Roche working on quality systems. Before that he was Group Leader Quality Control and Quality Manager for the Supply Center.
Dr Michael Möhlen  
*Valneva Austria GmbH, Vienna, Austria*  
Dr Möhlen is the Head of Technical Operations at Valneva Austria GmbH in Vienna and responsible for industrialisation of Vaccine candidates. This includes oversight as well to Quality Control and Clinical Serology. Until 2009 Dr Möhlen held various management positions in the Quality Control arena with Chiron and later Novartis Vaccines, including responsibility for raw material sampling and testing.

Dr Bernd Renger  
*Bernd Renger Consulting, Germany*  
Dr Bernd Renger is a member of the European Compliance Academy (ECA) Advisory Board and Immediate Past Chair of the European QP Association. Since 2011 he is running his own consultancy business. Before that he was VP of Quality Control at Vetter Pharma-Fertigung. He started his career 1977 at Hoechst AG as a research and development chemist. Since then, he has held several quality management positions at Mundipharma, Byk Gulden (now Takeda) and Baxter BioScience in Vienna.

Dr Martin Wesch  
*Wesch & Buchenroth, Law Office, Germany*  
Dr Martin Wesch is a lawyer specialised in medical and industrial law and working for the Stuttgart-based firm of lawyers Wesch & Buchenroth, which he founded in 2001. Since April 2002, he has been teaching industrial law at the University of Stuttgart. He is author of several publications, both in journals and books, to legal demands on quality assurance in manufacturing pharmaceuticals. In 2007 he received the Wallhaeusser Prize for publications in that field from Concept Heidelberg.

**Social Event**

On the evening of the first course day you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.
If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
   - until 2 weeks prior to the conference 10%,
   - until 1 week prior to the conference 50%,
   - within 1 week prior to the conference 100%.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-attendance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)!

ECA Conference
OOT Forum
22-23 October 2014, Prague, Czech Republic

On 22-23 October 2014, i.e. on Wednesday and Thursday of the same week, the OOT Forum will take place in the same hotel in Prague. At this event the Draft SOP Out of Expectation (OOE) and Out of Trend (OOT) Results compiled by ECA’s Analytical Quality Control Working Group will be presented and discussed.

All participants will have the opportunity to provide input to the contents of this new guidance document during the interactive ‘critique of the proposals’ sessions for each of these topics.

Become Part of the Peer Review Group to have a direct impact on the contents of this new document.

Further information about this conference can be received at www.gmp-compliance.org.

Register simultaneously for both courses and receive a 350 € discount (not valid for EU GMP Inspectorates).
Reservation Form (Please complete in full)

- Reduced Sampling / Reduced Testing
  20-21 October 2014, Prague, Czech Republic
- OOT Forum
  22-23 October 2014, Prague, Czech Republic

☐ Mr  ☐ Ms

Title, first name, surname

Company  Department

Important: Please indicate your company's VAT ID Number  P.O. Number, if applicable

Street/P.O. Box

City  Zip Code  Country

Phone/Fax

E-Mail (please fill in)

If the bill-to-address deviates from the specifications on the right, please fill out here:

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34
D-69007 Heidelberg
GERMANY